[Intensified conventional insulin therapy in children and adolescents with type I diabetes]. 1987

J Wolf, and E Wolf, and P Hürter
Kinderkrankenhaus auf der Bult, Hannover.

Children and adolescents with type-I-diabetes are examined with regard to the influence of Intensified Conventional Insulin Therapy (ICT) on metabolic control, insulin requirement and weight development. On average the period of treatment with ICT lasted 10 months (SD: 3 months). The average insulin requirement under ICT slightly increased from 0.82 to 0.87 I.U./kg BW. The need for longer acting insulin decreased from 0.5 to 0.35 I.U./kg BW. Snacks were not necessary. On average the insulin-BE quotient increased to 2.4 I.U./BE in the morning, 1.9.I.U./BE at lunch time and 2.1 I.U./BE at night. Compared to a group being treated with Conventional Insulin Therapy the quality of metabolic control improved. Within the ICT group the part of well controlled patients rose from 10 to 30% whereas the part of poorly controlled patients decreased from 30 to 10%. Provided that Continuous subcutaneous insulin infusion pumps (CSII) cannot be applied, ICT represents the best form of therapy for well educated and highly motivated diabetics aged 12 years old or more.

UI MeSH Term Description Entries
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D008297 Male Males
D009765 Obesity A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D003692 Delayed-Action Preparations Dosage forms of a drug that act over a period of time by controlled-release processes or technology. Controlled Release Formulation,Controlled-Release Formulation,Controlled-Release Preparation,Delayed-Action Preparation,Depot Preparation,Depot Preparations,Extended Release Formulation,Extended Release Preparation,Prolonged-Action Preparation,Prolonged-Action Preparations,Sustained Release Formulation,Sustained-Release Preparation,Sustained-Release Preparations,Timed-Release Preparation,Timed-Release Preparations,Controlled-Release Formulations,Controlled-Release Preparations,Extended Release Formulations,Extended Release Preparations,Slow Release Formulation,Sustained Release Formulations,Controlled Release Formulations,Controlled Release Preparation,Controlled Release Preparations,Delayed Action Preparation,Delayed Action Preparations,Formulation, Controlled Release,Formulations, Controlled Release,Prolonged Action Preparation,Release Formulation, Controlled,Release Formulations, Controlled,Sustained Release Preparation,Timed Release Preparation,Timed Release Preparations
D003920 Diabetes Mellitus A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.
D003922 Diabetes Mellitus, Type 1 A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence. Diabetes Mellitus, Brittle,Diabetes Mellitus, Insulin-Dependent,Diabetes Mellitus, Juvenile-Onset,Diabetes Mellitus, Ketosis-Prone,Diabetes Mellitus, Sudden-Onset,Diabetes, Autoimmune,IDDM,Autoimmune Diabetes,Diabetes Mellitus, Insulin-Dependent, 1,Diabetes Mellitus, Type I,Insulin-Dependent Diabetes Mellitus 1,Juvenile-Onset Diabetes,Type 1 Diabetes,Type 1 Diabetes Mellitus,Brittle Diabetes Mellitus,Diabetes Mellitus, Insulin Dependent,Diabetes Mellitus, Juvenile Onset,Diabetes Mellitus, Ketosis Prone,Diabetes Mellitus, Sudden Onset,Diabetes, Juvenile-Onset,Diabetes, Type 1,Insulin Dependent Diabetes Mellitus 1,Insulin-Dependent Diabetes Mellitus,Juvenile Onset Diabetes,Juvenile-Onset Diabetes Mellitus,Ketosis-Prone Diabetes Mellitus,Sudden-Onset Diabetes Mellitus
D003927 Diet, Diabetic A course of food intake prescribed for patients, that limits the amount of foods with a high GLYCEMIC INDEX. Diabetic Diet,Diabetic Diets,Diets, Diabetic
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005260 Female Females

Related Publications

J Wolf, and E Wolf, and P Hürter
June 1987, Vnitrni lekarstvi,
J Wolf, and E Wolf, and P Hürter
March 1988, Schweizerische Rundschau fur Medizin Praxis = Revue suisse de medecine Praxis,
J Wolf, and E Wolf, and P Hürter
January 1989, Pediatriia,
J Wolf, and E Wolf, and P Hürter
September 1998, Zeitschrift fur arztliche Fortbildung und Qualitatssicherung,
J Wolf, and E Wolf, and P Hürter
June 2005, Gynecologie, obstetrique & fertilite,
J Wolf, and E Wolf, and P Hürter
April 2014, Paediatric drugs,
J Wolf, and E Wolf, and P Hürter
April 1999, Diabetes, nutrition & metabolism,
J Wolf, and E Wolf, and P Hürter
October 1998, Acta paediatrica (Oslo, Norway : 1992). Supplement,
Copied contents to your clipboard!